EcoR1 Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

EcoR1 Capital’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,000,000	Closed	-$12.3M	–	52
2017 Q3	$12.3M	Hold	3,000,000	–	–	1.64%	18
2017 Q2	$11.1M	Hold	3,000,000	–	–	1.98%	13
2017 Q1	$12.4M	Buy	+3,000,000	New	+$12.6M	3.14%	10
2015 Q4	–	Sell	-157,250	Closed	-$2.58M	–	35
2015 Q3	$2.58M	Buy	+157,250	New	+$3.22M	1.18%	15

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EcoR1 Capital's CASC Position: Q4 2017 in Review

EcoR1 Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2017, closing a stake of 3,000,000 shares — an estimated $12.3M sold.

EcoR1 Capital first reported a position in CASC in Q3 2015 and held it in 4 quarters. The position peaked at $12.4M in Q1 2017. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

EcoR1 Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
EcoR1 Capital sold 3,000,000 Cascadian Therapeutics, Inc. shares in Q4 2017, an estimated $12.3M.
EcoR1 Capital first reported a position in Cascadian Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
EcoR1 Capital's Cascadian Therapeutics, Inc. position peaked at $12.4M in Q1 2017.
91 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2017.

Based on EcoR1 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.